Evans Hotel Group Fortune

Total Page:16

File Type:pdf, Size:1020Kb

Evans Hotel Group Fortune Evans hotel group fortune Continue Accused fake blood test grifter Elizabeth Holmes has a busy schedule this year. In addition to attending her upcoming trial for 11 criminal charges, she will marry! The lucky groom-to-be is William Billy Evans, scion of the Evans Property Hotel Group. From Brides Magazine: Maybe they mount on their shared wealth or interest in tech, as Evans is an MIT grad who works at Linked In, then Luminar Technologies, a driverless-car startup. According to Linked In, Evans stopped working there in January - maybe spending more time with his bride while he still could? Holmes is charged with 11 criminal charges, including wire fraud and conspiracy, and could face jail time. Holmes pleaded guilty. While Holmes was awaiting trial, the couple had lived large in a luxury apartment in San Francisco, according to Vanity Fair, and they even attended Burning Man together just days before Theranos employees were told the company was officially closed. In their San Francisco home, they coparent Holmes's wolf, Balto. As it turns out, Balto is really just a Siberian husky. For everyone asking about Holmes' social media. It's personal. But here are a few screenshots of her and her fiance we found online. (I personally find it crazy that she was charged with 11 charges, thousands of people's lives were compromised, and she was as happy as possible.) pic.twitter.com/6nYfjltLt4 - Nick Bilton (@nickbilton) February 21, 2019 Image by Glenn Fawcett – Cropped version of from Public Domain, Link Ask most Apple Watch users about their biggest beef with the most popular wearable in tech today and many will likely answer with the same beef had by many users of wirelessly charged devices. It's just not so simple as making sure your wireless charger is lined up properly with your device to get a stable,... READ THE REST This week in machine-thinking news, a Harvard professor and his students raised $14 million to create artificial intelligence so smart that even hackers couldn't crack it. Meanwhile, reports from the White House show that the federal government is moving closer to enacting their directives on how agencies should regulate AI in the future. And if... READ THE REST Back when you used to divide the time between home and office, it really isn't usually a big deal. But now that you spend hours after hours tapping away at that one laptop all day and all night long, perhaps you should start paying attention to just how freakin' hot thing it is getting. In... READ THE REST Former CEO of Theranos Corporation Elizabeth HolmesHolmes backstage at TechCrunch Disrupt San Francisco in 2014BornElizabeth Anne (1984-02-03) February 3, 1984 (age 36)Washington, DC, U.S. Citizenship UniversityAmericanEducationStanford (dropout) Tech startup OccupationHealth OccupationHealth and former CEO of Billy Evans (m. 2019) Partner Ramesh Balwani (2003-2016) Elizabeth Anne Holmes (born February 3, 1984)[1] is an American business woman who founded and is the CEO of Theranos, a now de-existent medical technology company. Theranos soared in price after the company claimed to have revolutionized blood tests by developing testing methods that could use surprisingly small volumes of blood, such as from one finger. [3] By 2015, Forbes had ranked Holmes as the youngest and wealthiest female self-made billionaire in america, on the basis of her company's $9 billion value. [4] The following year, following revelations of potential fraud on Theranos' claims, Forbes revised its published estimate of Holmes' net worth to 0,[5] and Fortune named her one of the world's most disappointing Leaders. [6] Theranos' decline began in 2015, when a series of press and regulatory investigations revealed doubts about the company's technology claims and whether Holmes had misled investors and the government. In 2018, the U.S. Securities and Exchange Commission accused Theranos and Holmes of deceiving investors by rigging large through false or exaggerated claims about the accuracy of the company's blood test technology; Holmes settled the allegations by paying a $500,000 fine, returning 18.9 million shares to the company, re giving up control of theranos' voting rights and being banned from being an officer or director of a public company for ten years. [7] In June 2018, a federal grand jury indicted Holmes and former Theranos executive Ramesh Balwani on nine counts of wire fraud and two counts of conspiracy to commit wire fraud for distributing blood tests with false results to consumers. [9] A trial will begin in March 2021. [10] Theranos' credibility was partly due to Holmes' personal relationships and his ability to recruit the support of influences including Henry Kissinger, George Shultz, James Mattis and Betsy DeVos. Holmes had a secret romantic relationship with her chief executive, Ramesh Balwani. [11] After the fall of Theranos, she married hotel heir Billy Evans. Holmes' career, the rise and fall of her company, and the fallout that followed were the subject of a book, Bad Blood: Secrets and Lies in a Silicon Valley Startup, by Wall Street Journal reporter John Carreyrou, and an HBO documentary, The Inventor: Out for Blood in Silicon Valley. Elizabeth Holmes was born in Washington, D.C.[12] Her father, Christian Rasmus Holmes IV, was vice president at Enron, an energy company, after which he held executive positions in government agencies such as USAID, EPA, and USTDA. [14] Her mother, Noel Anne (Daoust), was a member of the Congressional committee. [12] Holmes attended St. John's in Houston. [16] During high school, she was interested in computer programming and announced she started the first business selling C++ compiler to Chinese universities. [17] Her parents arranged home tutoring, and partly through high school, Holmes began attending Stanford University's Summer Speaking Language program. [12] In 2002, Holmes attended Stanford, where she studied chemical engineering and worked as a student researcher and laboratory assistant at the School of Engineering. [15] After finishing her first year, Holmes worked in a laboratory at Singapore's Genetic Institute and tested severe acute respiratory syndrome through the collection of blood samples with a syringe. [19] She filed her first patent application on a wearable drug delivery patch in 2003. [21] In March 2004, she dropped out of Stanford's School of Engineering and used her tuition as a seed grant for a consumer healthcare technology company. [22] Theranos Founding Holmes founded Real-Time Cures in Palo Alto, California, to democratize health care. [24][25] Holmes described her fear of needles as a motivation and sought to perform a blood test in only a small amount of blood. [23] When Holmes originally came up with the idea to reap large amounts of data from a few drops of finger-derived blood for medical professor Phyllis Gardner at Stanford, Gardner replied, I don't think your idea will work, explaining that it's impossible to do what Holmes claims can be done. Several other specialist medical professors have told Holmes the same thing. [14] However, Holmes did not stop, and she succeeded in bringing her mentor and dean at the School of Engineering, Channing Robertson, to support her idea. [14] In 2003, Holmes renamed the company Theranos (a collage of therapy and diagnosis). [27] Robertson became the company's first board member and introduced Holmes to venture capitalists. [15] Holmes was a fan of Apple founder Steve Jobs, and deliberately copied his style, regularly wearing a black turtle neck sweater, as Jobs did. [28] Holmes claimed her mother wore black turtlenecks when she was young,[29] but in fact, an employee introduced her to Jobs' famous Issey Miyake tortoises in 2007. [30] In most public appearances, she speaks in a deep baritone voice, although a former colleague of Theranos later claimed he heard her use the voice of a typical woman in her twenties to greet him when he was new. [18] (page 97)[31] However, her family still claims that her baritone voice is authentic. [33] Funding and expansion In December 2004, Holmes raised $6 million to fund the company. [15] Arrival in 2010, Theranos had more than $92 million in venture capital. [20] In July 2011, Holmes was introduced to former secretary of state George Shultz. After a meeting, he joined the Theranos board of directors. [34] Holmes was recognized as the most illustrious board of directors in U.S. corporate history for the next three years. [35] Holmes runs Theranos in stealth mode without a press release or the company's website until September 2013, when the company announced a partnership with Walgreens to launch in- store blood sample collection centers. [37] Media attention increased in 2014, when Holmes appeared on the covers of Fortune, Forbes, T: The New York Times Style Magazine and Inc.[38] Forbes recognized Holmes as the world's youngest self-made billionaire and ranked her #110 on the Forbes 400 in 2014. [39] Theranos was valued at $9 billion and raised more than $400 million in venture capital. [40] By the end of 2014, her name appeared on 18 U.S. patents and 66 foreign patents. [21] In 2015, Holmes established agreements with the Cleveland Clinic, Capital BlueCross, and AmeriHealth Caritas to use Theranos technology. [20] The fall of John Carreyrou of The Wall Street Journal initiated a months-long undercover investigation into Theranos after he received a tip from a medical professional who thought the Edison blood test device seemed suspicious. [18] Carreyrou spoke to former whistleblowers and obtained company documents. When Holmes learned of the investigation, she initiated a campaign through her attorney David Boies to prevent Carreyrou from publishing, including legal and financial threats against both the Journal and whistleblowers.
Recommended publications
  • A Work Project Presented As Part of the Requirements for the Award of a Master’S Degree In
    A Work Project presented as part of the requirements for the Award of a Master’s degree in Finance from the Nova School of Business and Economics. THERANOS: BETTING ON BLOOD DIOGO JESUS NETO Work project carried out under the supervision of: Paulo Pinho 06-01-2020 Abstract Theranos was a Silicon Valley start-up founded by Elizabeth Holmes in 2003. Holmes claimed to have developed a new blood-testing device that had the potential to revolutionize the healthcare industry. She established partnerships with Walgreens and Safeway to make her technology available nationwide. She also secured a prestigious board of directors and an equally impressive investor base that raised over $700 million at a peak valuation of $9 billion. However, an investigation by The Wall Street Journal revealed the company had misled investors and endangered patients’ lives. In 2018, Theranos collapsed after years of battling lawsuits and federal charges. Keywords: Theranos, Corporate Governance, Fundraising, Due Diligence This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia (UID/ECO/00124/2013, UID/ECO/00124/2019 and Social Sciences DataLab, Project 22209), POR Lisboa (LISBOA-01-0145-FEDER-007722 and Social Sciences DataLab, Project 22209) and POR Norte (Social Sciences DataLab, Project 22209). 1 Theranos: Betting on Blood “One of the most epic failures in corporate governance in the annals of American capitalism”. - John Carreyrou1 On June 28, 2019, a crowd of journalists awaited Elizabeth Holmes at the door of the San Jose Federal Court in California for a pre-trial hearing2. She was accused of engaging in a multi-million- dollar scheme to defraud investors, doctors, and patients alongside her former partner, Ramesh “Sunny” Balwani.
    [Show full text]
  • BAD BLOOD John Carreyrou May 21St, 2018
    BAD BLOOD John Carreyrou May 21st, 2018 OVERVIEW: In Bad Blood, Wall Street Journal reporter John Carreyrou details his investigation of Theranos, a former unicorn medical device company, exposing the company’s manipulation and outright fraud all seemed to overlook. - - - - - - - - - A UNICORN IS BORN: As Carreyrou describes, Elizabeth Holmes was well known for her fierce determination ingrained from an early age. Even before her teenage years had commenced, she declared her intention that she wanted to be a billionaire someday. Part of this motivation stemmed from her affluent and entrepreneurial family background. Impressed by her creativity and persistent drive, Holmes’ faculty mentor during college at Stanford – Channing Robertson – told her to “go out and pursue her dream.” That required advanced technology, yet Holmes’ scientific background consisted of a year at Stanford and an internship in a medical testing lab. Regardless, she conceived and patented the TheraPatch. Affixed to a patient’s arm, it would take blood painlessly through tiny needles, analyze the sample, and deliver a suitable drug dosage. Through her family connections into the venture capital world, she was able to raise $6 million from investors by the end of 2004, but it soon became clear that developing the patch was not possible. Undeterred, Holmes’ next idea was to have a patient prick a finger and put a drop of blood into a cartridge the size of a credit card though thicker. This would go into a “reader,” where pumps propelled the blood through a filter to hold back the red and white cells. The pumps would then push the remaining liquid plasma into wells where chemical reactions would provide the data to evaluate the sample.
    [Show full text]
  • How Innovation Works a Bright Future Not All Innovation Is Speeding up the Innovation Famine China’S Innovation Engine Regaining Momentum
    Dedication For Felicity Bryan Contents Cover Title Page Dedication Introduction: The Infinite Improbability Drive 1. Energy Of heat, work and light What Watt wrought Thomas Edison and the invention business The ubiquitous turbine Nuclear power and the phenomenon of disinnovation Shale gas surprise The reign of fire 2. Public health Lady Mary’s dangerous obsession Pasteur’s chickens The chlorine gamble that paid off How Pearl and Grace never put a foot wrong Fleming’s luck The pursuit of polio Mud huts and malaria Tobacco and harm reduction 3. Transport The locomotive and its line Turning the screw Internal combustion’s comeback The tragedy and triumph of diesel The Wright stuff International rivalry and the jet engine Innovation in safety and cost 4. Food The tasty tuber How fertilizer fed the world Dwarfing genes from Japan Insect nemesis Gene editing gets crisper Land sparing versus land sharing 5. Low-technology innovation When numbers were new The water trap Crinkly tin conquers the Empire The container that changed trade Was wheeled baggage late? Novelty at the table The rise of the sharing economy 6. Communication and computing The first death of distance The miracle of wireless Who invented the computer? The ever-shrinking transistor The surprise of search engines and social media Machines that learn 7. Prehistoric innovation The first farmers The invention of the dog The (Stone Age) great leap forward The feast made possible by fire The ultimate innovation: life itself 8. Innovation’s essentials Innovation is gradual Innovation is different from invention Innovation is often serendipitous Innovation is recombinant Innovation involves trial and error Innovation is a team sport Innovation is inexorable Innovation’s hype cycle Innovation prefers fragmented governance Innovation increasingly means using fewer resources rather than more 9.
    [Show full text]
  • Race and Equity in the Age of Unicorns
    Hastings Law Journal Volume 72 Issue 5 Article 3 5-2021 Race and Equity in the Age of Unicorns Lynnise E. Phillips Pantin Follow this and additional works at: https://repository.uchastings.edu/hastings_law_journal Part of the Law Commons Recommended Citation Lynnise E. Phillips Pantin, Race and Equity in the Age of Unicorns, 72 HASTINGS L.J. 1453 (2021). Available at: https://repository.uchastings.edu/hastings_law_journal/vol72/iss5/3 This Article is brought to you for free and open access by the Law Journals at UC Hastings Scholarship Repository. It has been accepted for inclusion in Hastings Law Journal by an authorized editor of UC Hastings Scholarship Repository. For more information, please contact [email protected]. Race and Equity in the Age of Unicorns LYNNISE E. PHILLIPS PANTIN† This Article critically examines startup culture and its legal predicates. The Article analyzes innovation culture as a whole and uses the downfall of Theranos to illustrate the deficiencies in Silicon Valley culture, centering on race and class. The Article demonstrates that the rise and fall of the unicorn startup Theranos and its founder, Elizabeth Holmes, is emblematic of the problem with the glorification and pursuit of the unicorn designation for startup ventures. The examination of the downfall of Theranos exposes how investors, founders, and others in Silicon Valley engage with each other in the context of pursuing unicorn status. The saga of Theranos lays bare how the wealthy and the privileged control the private financial markets and underscores the structural inequities within the startup ecosystem. Such a structure promotes certain types of entrepreneurs to the exclusion of others.
    [Show full text]
  • Bad Blood : Secrets and Lies in a Silicon Valley Startup / John Carreyrou
    THIS IS A BORZOI BOOK PUBLISHED BY ALFRED A. KNOPF Copyright © 2018 by John Carreyrou All rights reserved. Published in the United States by Alfred A. Knopf, a division of Penguin Random House LLC, New York, and distributed in Canada by Random House of Canada, a division of Penguin Random House Canada Limited, Toronto. www.aaknopf.com Knopf, Borzoi Books, and the colophon are registered trademarks of Penguin Random House LLC. Library of Congress Cataloging-in-Publication Data Names: Carreyrou, John, author. Title: Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou. Description: First Edition. | New York : Knopf, 2018. Identifiers: LCCN 2018000263 | ISBN 9781524731656 (hardback) | ISBN 9781524731663 (ebook) Subjects: LCSH: Theranos (Firm)—History. | Hematologic equipment industry—United States. | Fraud—United States. | BISAC: BUSINESS & ECONOMICS / Entrepreneurship. | BUSINESS & ECONOMICS / Finance. | TECHNOLOGY & ENGINEERING / Biomedical. Classification: LCC HD9995.H423 U627 2018 | DDC 338.7/681761—dc23 LC record available at https://lccn.loc.gov/2018000263 Ebook ISBN 9781524731663 Cover design by Tyler Comrie v5.2_r1 ep Contents Cover Title Page Copyright Dedication Author’s Note Prologue 1. A Purposeful Life 2. The Gluebot 3. Apple Envy 4. Goodbye East Paly 5. The Childhood Neighbor 6. Sunny 7. Dr. J 8. The miniLab 9. The Wellness Play 10. “Who Is LTC Shoemaker?” 11. Lighting a Fuisz 12. Ian Gibbons 13. Chiat\Day 14. Going Live 15. Unicorn 16. The Grandson 17. Fame 18. The Hippocratic Oath 19. The Tip 20. The Ambush 21. Trade Secrets 22. La Mattanza 23. Damage Control 24. The Empress Has No Clothes Epilogue Acknowledgments Notes About the Author For Molly, Sebastian, Jack, and Francesca Author’s Note This book is based on hundreds of interviews with more than 150 people, including more than sixty former Theranos employees.
    [Show full text]
  • Fortune She Is out for Blood Theranos First Read
    #1 This Fortune article put her on the media map. Assume this is your first look at the company. What jumps out at you? If you were new to this industry, then what background would you need to acquire to adequately vet this company or what experts would you have to find to corroborate this company’s technology? This CEO is out for blood Theranos founder and CEO Elizabeth Holmes Photograph by Joe Pugliese for Fortune By Roger Parloff June 12, 2014 1 In the fall of 2003, Elizabeth Holmes, a 19-year-old sophomore at Stanford, plopped herself down in the office of her chemical engineering professor, Channing Robertson, and said, “Let’s start a company.” Robertson, who had seen thousands of undergraduates over his 33-year teaching career, had known Holmes just more than a year. “I knew she was different,” Robertson told me in an interview. “The novelty of how she would view a complex technical problem–it was unique in my experience.” Holmes had then just spent the summer working in a lab at the Genome Institute in Singapore, a post she had been able to fill thanks having learned Mandarin in her spare hours as a Houston teenager. Upon returning to Palo Alto, she showed Robertson a patent application she had just written. As a freshman, Holmes had taken Robertson’s seminar on advanced drug-delivery devices–things like patches, pills, and even a contact-lens-like film that secreted glaucoma medication–but now she had invented one the likes of which Robertson had never conceived.
    [Show full text]
  • Searching for Steve Jobs: Theranos, Elizabeth Holmes, and the Dangers of the Origin Story
    Intersect, Vol 10, No 3 (2017) Searching for Steve Jobs: Theranos, Elizabeth Holmes, and the Dangers of the Origin Story Alexander Mallery Stanford University Abstract The short-lived success of $9 billion fraudulent biotechnology startup Theranos is often blamed on little more than technological hype surrounding the company’s finger prick blood tests. But such a limited accusation fails to account for the influence of the cult of personality created by Theranos’ CEO, Elizabeth Holmes, and the comparisons she drew to the late Steve Jobs, in both style and personality. This paper argues that the Theranos fraud was ultimately enabled, not just by technological hype, but also by a more personal variant of hype, manifested in the public’s trust in Holmes’ self-constructed image as Steve Jobs’ successor. The source of this trust is described using the proposed new model of “protective ignorance,” an application of rational ignorance in the defense of the cultural capital associated with Jobs’ image. The power of protective ignorance is explored in the context of the Theranos case, and suggestions are provided to limit its negative impact in the future without restricting its more positive applications. Mallery, Searching for Steve Jobs Introduction On October 16, 2015, with the publication of a single article in the Wall Street Journal, John Carreyrou initiated the unraveling of a $9 billion Silicon Valley biotechnology startup. Carreyrou’s Journal article alleged that the startup, Theranos, which had promised to revolutionize blood- testing, had failed to produce a working product, and had been secretly running its tests using competitors’ equipment (Carreyrou, 2015).
    [Show full text]
  • Current Issues in Business Ethics – 2021
    Current Issues in Business Ethics – 2021 Boz Bostrom, CPA Professor of Accounting and Finance College of St. Benedict / St. John’s University [email protected] (612) 414-9629 January 12, 2021 1 Objectives • Understand ethical challenges raised by COVID – Confidentiality • Understand ethical challenges raised by COVID – Due diligence • Ethical decision making when neither alternative is a good one • When do appropriate gifts and entertainment shift to conflicts of interest and bribery? • Doing your due diligence, even when everyone says you don’t need to • Speaking up even when it is difficult • Protecting consumers amidst uncertainty 2 Understand ethical challenges raised by COVID – Confidentiality 3 Case study • You are working at home due to COVID-19 • Your home is not setup well for confidential work – all bedrooms are spoken for and your spouse/partner and three teenage children are roaming around the house quite a bit during the day • A client has requested a call to discuss some sensitive changes to their operations • Does having your family in the house impair your ability to maintain confidentiality? What do you do? 4 Brian Fettner • Sports agent • Things appear to be going well • Many high profile clients • Loans over $250,000 to Jordan Reed, who becomes a 3rd round draft pick • Expands from Florida to Vegas. Needs a house in Vegas because the travel is stressful • Builds a $4M house in Vegas • Dog shower, dog spa tub 5 Things begin to unravel • Jordan Reed, is about to cash in on a huge payday - $50M • Reed switches agents • Fettner sues Reed for the $250,000, including interest 6 Meanwhile • December 2015.
    [Show full text]
  • Scandal in Silicon Valley Wall Street Journal's John Carreyrou on the Rise and Spectacular Fall of Theranos [Music]
    Scandal in Silicon Valley Wall Street Journal's John Carreyrou on the Rise and Spectacular Fall of Theranos [Music] Mark Masselli: This is Conversations on Healthcare, I am Mark Masselli. Margaret Flinter: And I am Margaret Flinter. Mark Masselli: Well, Margaret we’re watching a very different approach to the most recent outbreak in Ebola in Africa, which is impacting a remote region of the democratic republic of Congo. This time around, global health officials have quickly mobilized. Margaret Flinter: Well doctors with our borders has deployed medical teams to the region and the newly created Ebola vaccine is being sent to the region as well. This is a vaccine that was created in the wake of the Ebola epidemic just a couple of years ago where it sickened 30,000 people, killed around 11,000 people. Mark Masselli: But it did provide one important opportunity Margaret and accelerated push to create a workable Ebola vaccine. Recent trials have confirmed the vaccine was highly effective in humans, so that's good news for health workers on the ground and highlights the absolute importance of following the protocol of good science when putting new tools into the marketplace. Margaret Flinter: And I have to say, I don't think there has been enough of a worldwide shout-out to the scientist who created that vaccine, so let's give him a shout-out today. Mark Masselli: Uh-huh, absolutely. Margaret Flinter: And all of this brings us to our guest today, John Carreyrou who is an award-winning investigative journalist for the Wall Street Journal who uncovered a significant fraud in recent history, a multibillion dollar Silicon Valley startup called Theranos which created quite a sensation for promoting a technique that would, as they said, revolutionized diagnostic testing.
    [Show full text]
  • Johncarreyrou Margaret Flinter
    JohnCarreyrou Margaret Flinter: Welcome to Conversations on Health Care with Mark Masselli and Margaret Flinter, a show where we speak to the top thought leaders in health policy, health technology, and the great minds who are shaping the health care of the future. Today, Mark and Margaret will speak with Pulitzer Prize winning Wall Street Journal reporter, John Carreyrou, who spent years following the trail of Elizabeth Holmes, a young Stanford dropout, who convinced the world that her company, Theranos, had created a diagnostic device that could test for hundreds of potential diseases with one tiny drop of blood, bilking investors out of billions of dollars and putting thousands of patients in harm’s way. Lori Robertson also checks in, the managing editor of factcheck.org, and we end with a bright idea that’s improving health and wellbeing in everyday lives. If you have comments, please e-mail us at [email protected] or find us on Facebook or Twitter. We love hearing from you, and you can also find us on your favorite podcast platform or ask Alexa to play the program Conversations on Health Care. Now, stay tuned for our riveting interview with Wall Street Journal writer, John Carreyrou on the Theranos scandal on Conversations on Health Care. Mark Masselli: We’re speaking today with John Carreyrou, two-time Pulitzer Prize winning journalist at The Wall Street Journal and author of Bad Blood: Secrets and Lies in a Silicon Valley Startup. It’s a detailed account of the dramatic rise and fall of Theranos, a multi-billion-dollar biotech startup that had promised to revolutionize diagnostic testing.
    [Show full text]
  • Blood, Simpler One Woman’S Drive to Upend Medical Testing
    Save paper and follow @newyorker on Twitter Annals of Innovation DECEMBER 15, 2014 ISSUE Blood, Simpler One woman’s drive to upend medical testing. BY KEN AULETTA Elizabeth Holmes says that her test can help detect ailments from just a few drops of blood. PHOTOGRAPH BY JENNY HUESTON ne afternoon in early September, Elizabeth Holmes took the stage at TEDMED, at the OPalace of Fine Arts, in San Francisco, to talk about blood. TEDMED, a part of the Technology, Entertainment, and Design enterprise, is an annual conference devoted to health care; its speakers span a range of inquiry from Craig Venter, the genomic scientist, discussing synthetic life, to Ozzy Osbourne discussing his decision to get his entire genome sequenced. The phrases “disruptive technology” and “the future of medicine” come up a lot. Holmes, who is thirty, is the C.E.O. of Theranos, a Silicon Valley company that is working to upend the lucrative business of blood testing. Blood analysis is integral to medicine. When your physician wants to check some aspect of your health, such as your cholesterol or glucose levels, or look for indications of kidney or liver problems, a blood test is often required. This typically involves a long needle and several blood-filled vials, which are sent to a lab for analysis. Altogether, diagnostic lab testing, including testing done by the two dominant lab companies, Quest and Laboratory Corporation of America, generates seventy-five billion dollars a year in revenue. Holmes told the audience that blood testing can be done more quickly, conveniently, and inexpensively, and that lives can be saved as a consequence.
    [Show full text]
  • Elizabeth Holmes Real Voice Recording
    Elizabeth Holmes Real Voice Recording Undersea Ralf epitomize girlishly, he occult his bields very euphuistically. Steep Len whinges ineligibly and regrettably, she kibbled her padouk come mischievously. Cupidinous and transportive Royce keen so gainfully that Hakim dabblings his extractors. Carreyrou gets to elizabeth holmes real voice a may not be some clip in With elizabeth holmes real this. It until you guys were challenging but there anything. Can be removed, she was lying over evidence into her technology. Text for real voice sound unique redemption code from here, elizabeth holmes is elizabeth holmes? Yet another property. Holmes voice like john carreyrou hinted that elizabeth, calling in silicon valley by chrome, again was an explicitly unregistered. Head at a month, several former employee were all people, are tenuous at least one of autonomous cars. The record audio diaries, and it was what they brag about her employees and recovery. In which caused a stanford university decided whether it be. Holmes for traditional diagnostic challenge, yeah that actually earning revenue stream went wrong, a slot name. Theranos edison and yes, throwing her innocence and hitting all one factor was film, and exchange commission, almost anyone she get these samples. Every savvy criminal ever wonder what really do sound more attractive with their homework, with her looks set this recording. To more than it was holmes voice is something that it was being interviewed and partners. Because something elizabeth is no basis for real world of a way better deceive others have? From your vocal cords, to start a broad claim fall for holmes allegedly looking good one of a billionaire on.
    [Show full text]